Deflazacort Vs. Prednisolone in Acute-stage ABPA

Launched by POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH · Jan 10, 2020

Keywords

ClinConnect Summary

This clinical trial is comparing two medications, deflazacort and prednisolone, to see which one works better and causes fewer side effects for treating acute-stage allergic bronchopulmonary aspergillosis (ABPA) in people with asthma. ABPA is a condition caused by an allergy to a fungus called Aspergillus, which can lead to serious breathing problems. Both medications are steroids that help reduce inflammation and control the immune system, but deflazacort is thought to have fewer side effects, especially weight gain, compared to prednisolone.

To participate in this study, you must be between 18 and 65 years old and have asthma along with specific allergy test results. You should have high levels of a particular allergy marker in your blood and meet other criteria related to your health. Participants will take one of the two medications and will be monitored for safety and effectiveness. It’s important to note that if you have certain health conditions like diabetes or have previously been treated for ABPA, you may not be eligible for this trial. The trial is currently active but not recruiting new participants at this time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients aged 18-65 years will be included in the study if they meet the modified ISHAM-ABPA working group criteria defined by the presence of all the following three criteria:
• • Asthma
• • A.fumigatus-specific IgE levels \> 0.35 kUA/L
• * Elevated serum total IgE levels \> 1000 IU/mL; and two of the following criteria:
• • Presence of elevated A fumigatus-specific IgG \>27 mgA/L;
• • Radiographic pulmonary opacities consistent with ABPA
• • Peripheral blood eosinophil count \>500/µL.
• Exclusion Criteria:
• • Taken any prior treatment for ABPA (systemic glucocorticoids, antifungal drugs)
• • Failure to give informed consent
• • Enrollment in another trial of ABPA
• • Pregnancy
• • Any of the following comorbidity: diabetes mellitus, glaucoma, chronic liver disease and chronic kidney disease